The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | QUINTESSENTIAL: a Phase II trial of arlo-cel, a GPRC5D-directed CAR T-cell therapy, in R/R myeloma
Ciara Freeman, MD, PhD, Moffitt Cancer Center, Tampa, FL, discusses the QUINTESSENTIAL trial (NCT06297226), a Phase II study evaluating arlocabtagene autoleucel (arlo-cel), a CAR T-cell therapy targeting GPRC5D, in patients with relapsed/refractory (R/R) multiple myeloma (MM) who have been exposed to all major classes of drugs and are considered quad-exposed. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
